Kluin‐Neleman 1979.

Study characteristics
Methods	Randomised, double‐blind, 2‐period cross‐over study
Participants	11 people (10 men/1 woman) aged 21‐53 years Tumour types: Hodgkin's or non‐Hodgkin's lymphoma Chemotherapy regimens: mitoxine 6 mg/m2 (maximum 10 mg), vincristine 1.4 mg/m2 (maximum 2 mg) IV on days 1 and 8. Procarbazine 100 mg/m2 and prednisone 40 mg/m2 oral days 1‐14 for 6 cycles with intervals of 2 weeks Chemotherapy emetogenicity: high
Interventions	Dronabinol 10 mg/m2 orally, n = 11 Placebo, n = 11
Outcomes	Episodes of nausea and vomiting at end of day of therapy, feeling high, dizziness, hallucinations
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	17 participants received THC, 11 participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Washout period 2 weeks. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical gelatin capsules were used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double‐blind" and "identical gelatin capsules used"